New Internationalist

Novartis vs India: the court will decide

Web exclusive

Generic drugs made in India are saving lives around the world. But if the country’s Supreme Court rules in favour of Big Pharma, all that could change, says Simon Reid-Henry.

Photo by Martin Lopatka under a CC Licence
Photo by Martin Lopatka under a CC Licence

The Indian Supreme Court opens today for the concluding stage of a long-running assault on India’s patent law by drug giant Novartis.

For six years Novartis has been trying to get Indians to pay market price for one of its patented drugs, Glivec – a life-saving anti-cancer medicine. Like other Big Pharma, Novartis believes that middle-income countries such as India and Brazil are no longer dirt poor and should now be paying their way for medicines. It argues that India should button up and follow the 40 other countries that already recognize the patent on Glivec.

But this is rather like saying it thinks India should jump under a bus on the grounds that others have been coaxed into doing so, and it sidesteps what is really at stake in today’s case. Because while India is a lucrative market and Glivec a blockbuster drug – with a price tag of around 10 times the generic equivalent – the tenacity with which Novartis has clawed its way through the Indian legal system to bring its case before the Supreme Court belies a far more significant pay off.

India now exports as much as 50 per cent of its $15 billion generics industry to other countries and supplies many of the medicines used in global health treatment programmes around the world

By challenging not only the rejection of its own patent, but the constitutional legality of a key part of India’s patent law, Novartis has in effect teed up an important litmus test of the sorts of flexibilities that emerging economies can draw upon to protect their own domestic industries under governing WTO TRIPS (trade-related aspects of intellectual property rights) legislation.

This means that if Novartis ultimately win the case, they not only open up the potentially lucrative Indian market for their own drugs, they will also force all Indian pharmaceutical producers to think twice about the sorts of drugs they make cheap versions of in future. And by further pegging India to rich-country levels of patent protection, the ultimate consequence may be to undermine the country’s entire generics revolution.

An Indian lifeline

The implications of this reach far beyond India’s borders. For while it is well known that India produces cheap generic drugs, it is less well known that India now exports as much as 50 per cent of its $15 billion generics industry to other countries, or that Indian generics supply many of the medicines used in global health treatment programmes around the world. The medical group Médicins Sans Frontières (MSF) source 80 per cent of the HIV drugs that they use across the developing world from India, for example. Which makes India, as MSF spokesperson Leena Menghaney puts it, ‘literally the lifeline of patients in the developing world’.

But that lifeline itself is protected by the very part of India’s patent law that Novartis seeks to challenge. Section 3d, as it is known, was a public health safeguard that India adopted when it became officially TRIPS compliant in 2005. It is specifically intended to prevent what Novartis have for years been trying to do with Glivec: namely to extend the life of an older patent through clinically insignificant modifications, a practice known as ‘ever-greening’.

This case will – by luck or by design – undermine the legal room for maneouvre that India’s generics revolution relies upon

Novartis strongly reject this. They say that activist groups like MSF, ‘are confusing the issue’ by claiming that the case will affect generic medicines produced in India for the developing world. It is hard to feel all that sympathetic for Novartis, here. India has only become the pharmacy of the developing world because until now it has been so easy for them to undercut Big Pharma’s preference for a vastly overpriced market. And proven unwilling to compete on price, Novartis’ current actions now further paint them in the well-slippered guise of the monopoly capitalist, banging their fists on the table and crying foul play while doing all they can at the same time to rewrite the rules in their favour: they must surely know that by cranking up the risks for Indian generic producers this case will – by luck or by design – undermine the legal room for maneouvre that India’s generics revolution relies upon.

Regardless of the outcome, the world should follow what happens in New Delhi from today with interest. Novartis’ backdoor attempt to lob the hand grenade of Western monopoly rights into India’s well-functioning generics laboratories is likely to be just one of many coming salvos in the battle to meet, and to profit from, the health needs of those parts of the developing world with a dollar or two in their back pocket. Expect the EU-India Free Trade Agreement to be the next to try. And expect many people’s health to suffer if either attempt is successful.

Simon Reid-Henry is a lecturer in geography at Queen Mary, University of London and the founding director of the Centre for the Study of Global Security and Development. His most recent book is The Cuban Cure: Reason and Resistance in Global Science. He is currently based in Oslo.

Further New Internationalist coverage on related issues:

Mari Marcel Thekaekara on India's drug lifeline under threat

Dinyar Godrej: Eight things you should know about patents

Comments on Novartis vs India: the court will decide

Leave your comment







 

  • Maximum characters allowed: 5000
  • Simple HTML allowed: bold, italic, and links

Registration is quick and easy. Plus you won’t have to re-type the blurry words to comment!
Register | Login

  1. #1 JAMES 29 Nov 11

    SHOULD BE IMBLEMENT ESENCIAL DRUG CONTROL ACT AT INDIA. BAN PATTENDING SYSTEM IMMEDIATLY.IMBLEMENT MORE TAXES TO NOVARTIS,GLAXO,PIYZER,AND ALL DRUG GIANTS.

  2. #2 onedaywonder 30 Nov 11

    As for Glivec's sordid origins - here's an old New Internationalist article that outlines how despicably Novartis treated the South Korean patients it used to test this drug.
    http://www.newint.org/features/2003/11/01/the-great-health-grab/

  3. #3 Raghavan 17 Feb 12

    Since ancient times medical treatment and education were free in India as the sages realized that these two are the backbone of society's good health. The capitalistic west just believes in making money out of everything and there is no limit to the greed. Capitalism is also another form of extremism propagated by the powerful for the powerful. It is no different from terrorism and its reach affects the whole globe. Just the form is different. Greed must have maximum checks and balances for our planet to survive and everyone should fight excessive corporate greed. This is the basis of Occupy wall Street movement. People around the globe are waking up and these atrocities cannot continue for long!

Subscribe to Comments for this articleArticle Comment Feed RSS 2.0

Guidelines: Please be respectful of others when posting your reply.

Get our free fortnightly eNews

Multimedia

Videos from visionOntv's globalviews channel.

Related articles

Recently in Web exclusives

All Web exclusives

Popular tags

All tags

New Internationalist Magazine Issue 436

If you would like to know something about what's actually going on, rather than what people would like you to think was going on, then read the New Internationalist.

– Emma Thompson –

A subscription to suit you

Save money with a digital subscription. Give a gift subscription that will last all year. Or get yourself a free trial to New Internationalist. See our choice of offers.

Subscribe